The Re-Emerging Concept of Personalized Healthcare

• Poisal JA , TrufferC, SmithS et al.: Health spending projections through 2016: modest changes obscure part D‘s impact. Health Aff. (Millwood)26(2) , W242–W253 (2007).
   PubMed Web of Science ®Google Scholar
• The World Health Report 2000. WHO, Geneva, Switzerland (2000).
   Google Scholar
• Blower PE , ChungJH, VerducciJS et al.: MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther.7(1) , 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Evans RS , LloydJF, StoddardGJ, Nebeker JR, Samore MH: Risk factors for adverse drug events: a 10-year analysis. Ann. Pharmacother.39 , 1161–1168 (2005).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, DownesK et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J.5 , 262–270 (2005).
   PubMed Web of Science ®Google Scholar
• Takahashi H , WilkinsonGR, CaracoY et al.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther.73 , 253–263 (2003).
   PubMed Web of Science ®Google Scholar
• Landefeld CS , BeythRJ: Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.Am. J. Med.95 , 315–328 (1993).
   PubMed Web of Science ®Google Scholar
• Gage B , EbyC, JohnsonJ et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Schelleman H , ChenZ, KealeyC et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther.81(5) , 742–747 (2007).
   PubMed Web of Science ®Google Scholar
• Rieder MJ , ReinerAP, GageBF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.352 , 2285–2293 (2005).
   PubMed Web of Science ®Google Scholar
• Higashi MK , VeenstraDL, KondoLM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA287 , 1690–1698 (2002).
   PubMed Web of Science ®Google Scholar
• McClain MR , PalomakiGE, PiperM, HaddowJE: A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Genet. Med.10 , 89–98 (2008).
   PubMed Web of Science ®Google Scholar
• Landefeld CS , GoldmanL: Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.Am. J. Med.87 , 144–152 (1989).
   PubMed Web of Science ®Google Scholar
• Caraco Y , BlotnickS, MuszkatM: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Clin. Pharmacol. Ther.83 , 460–470 (2008).
   PubMed Web of Science ®Google Scholar
• Schwarz UI , RitchieMD, BradfordY et al.: Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med.358 , 999–1008 (2008).
   PubMed Web of Science ®Google Scholar
• Bussey HI , WittkowskyAK, HylekEM, WalkerMB: Genetic testing for warfarin dosing? Not yet ready for prime time.Pharmacotherapy28(2) , 141–143 (2008).
   PubMed Web of Science ®Google Scholar
• Gage BF , LeskoLJ: Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.J. Thromb. Thrombolysis25(1) , 45–51 (2008).
   PubMed Web of Science ®Google Scholar
• Shurin SB , NabelEG: Pharmacogenomics – ready for prime time?N. Engl. J. Med.358(10) , 1061–1063 (2008).
   PubMed Web of Science ®Google Scholar
• Wang D , ChenH, MomaryKM, Cavallari LH, Johnson JA, Sadee W: Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood112(4) , 1013–1021 (2008).
   PubMed Web of Science ®Google Scholar
• Caldwell MD , AwadT, JohnsonJA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood111(8) , 4106–4112 (2008).
   PubMed Web of Science ®Google Scholar
• Phillips KA , VeenstraDL, OrenE, LeeJK, SadeeW: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.JAMA286 , 2270–2279 (2001).
   PubMed Web of Science ®Google Scholar
• Scata KA , El-DeiryWS: p53, BRCA1 and breast cancer chemoresistance.Adv. Exp. Med. Biol.608 , 70–86 (2007).
   PubMed Web of Science ®Google Scholar
• Dent R , ClemonsM: Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.Cancer Treat. Rev.32 , 144–148 (2006).
   PubMed Web of Science ®Google Scholar
• Druker BJ , GuilhotF, O‘BrienSG et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355 , 2408–2417 (2006).
   PubMed Web of Science ®Google Scholar
• Calin GA , LiuCG, SevignaniC et al.: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA101 , 11755–11760 (2004).
   PubMed Web of Science ®Google Scholar
• He H , JazdzewskiK, LiW et al.: The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA102 , 19075–19080 (2005).
   PubMed Web of Science ®Google Scholar
• Lu J , GetzG, MiskaEA et al.: MicroRNA expression profiles classify human cancers. Nature435 , 834–838 (2005).
   PubMed Web of Science ®Google Scholar

Websites

• US FDA Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels www.fda.gov/cder/genomics/genomic_ biomarkers_table.htm
   Google Scholar
• Harvard Medical School – Partners Healthcare Center for Genetics and Genomics www.hpcgg.org/
   Google Scholar
• Emory University and the Georgia Institute of Technology Predictive Health Institute http://predictivehealth.emory.edu/
   Google Scholar
• Personalized Genetics/Genomics: Interview with Steven Murphy, MD. Accessed 30August2007www.scientificblogging.com/ncurse/personalized_genetics_genomics_interview_with_steven_murphy_md
   Google Scholar